These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
91 related articles for article (PubMed ID: 29312995)
1. Chen JJ; Zhou W; Cai N; Chang G Biomed Res Int; 2017; 2017():3521481. PubMed ID: 29312995 [TBL] [Abstract][Full Text] [Related]
2. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927 [TBL] [Abstract][Full Text] [Related]
3. Leukemia stem cells. Luo L; Han ZC Int J Hematol; 2006 Aug; 84(2):123-7. PubMed ID: 16926133 [TBL] [Abstract][Full Text] [Related]
4. [Establishment of Human Acute B-Lymphoblastic Leukemia--NOD/SCID Xenotransplant Mouse Model]. Zhang X; Deng Y; Chen FL; Fang YJ; Zhang W; Yu L Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Jun; 23(3):623-6. PubMed ID: 26117005 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463 [TBL] [Abstract][Full Text] [Related]
6. Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model. Fritz V; Louis-Plence P; Apparailly F; Noël D; Voide R; Pillon A; Nicolas JC; Müller R; Jorgensen C Bone; 2007 Apr; 40(4):1032-40. PubMed ID: 17251073 [TBL] [Abstract][Full Text] [Related]
7. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice. Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632 [TBL] [Abstract][Full Text] [Related]
8. Good engraftment of B-cell precursor ALL in NOD-SCID mice. Baersch G; Möllers T; Hötte A; Dockhorn-Dworniczak B; Rübe C; Ritter J; Jürgens H; Vormoor J Klin Padiatr; 1997; 209(4):178-85. PubMed ID: 9293448 [TBL] [Abstract][Full Text] [Related]
9. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812 [TBL] [Abstract][Full Text] [Related]
10. IL-2Ralpha-Directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Ralpha interaction. Phillips KE; Herring B; Wilson LA; Rickford MS; Zhang M; Goldman CK; Tso JY; Waldmann TA Cancer Res; 2000 Dec; 60(24):6977-84. PubMed ID: 11156399 [TBL] [Abstract][Full Text] [Related]
11. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone. Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692 [TBL] [Abstract][Full Text] [Related]
12. [Comparison of the Tumor-forming Rate between the SCID and NOD/SCID Mice used to Set up Acute Myeloid Leukemia Model]. Yang H; Liu JX; Zhou ZP; Liu L; Zhang Y Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Apr; 23(2):328-34. PubMed ID: 25948180 [TBL] [Abstract][Full Text] [Related]
13. Osteolytic lesions as a presenting sign of acute myeloid leukemia. Lima CS; Pinto Neto JV; da Cunha ML; Vassallo J; Cardinalli IA; De Souza CA Haematologia (Budap); 2000; 30(4):325-31. PubMed ID: 11204032 [TBL] [Abstract][Full Text] [Related]
15. Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells. Askmyr M; Ågerstam H; Lilljebjörn H; Hansen N; Karlsson C; von Palffy S; Landberg N; Högberg C; Lassen C; Rissler M; Richter J; Ehinger M; Järås M; Fioretos T Blood Cancer J; 2014 Dec; 4(12):e269. PubMed ID: 25501026 [TBL] [Abstract][Full Text] [Related]
16. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Feuring-Buske M; Gerhard B; Cashman J; Humphries RK; Eaves CJ; Hogge DE Leukemia; 2003 Apr; 17(4):760-3. PubMed ID: 12682634 [TBL] [Abstract][Full Text] [Related]
17. NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease. Lawson MA; Paton-Hough JM; Evans HR; Walker RE; Harris W; Ratnabalan D; Snowden JA; Chantry AD PLoS One; 2015; 10(3):e0119546. PubMed ID: 25768011 [TBL] [Abstract][Full Text] [Related]
18. Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastases. Morrissey C; Kostenuik PL; Brown LG; Vessella RL; Corey E BMC Cancer; 2007 Aug; 7():148. PubMed ID: 17683568 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice. Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738 [TBL] [Abstract][Full Text] [Related]
20. Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone. Lee Y; Schwarz E; Davies M; Jo M; Gates J; Wu J; Zhang X; Lieberman JR J Orthop Res; 2003 Jan; 21(1):62-72. PubMed ID: 12507581 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]